Long-acting injectable antipsychotics: An underutilized treatment option

Journal of Clinical Psychiatry

Volumn 75, Issue 11, 2014, Pages 1263-1265

  Heres, Stephan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PLACEBO; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; HUMAN; MEDICAL DECISION MAKING; NOTE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; FEMALE; MALE;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 84927566310     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14com09541     Document Type: Note

References (28)

1. Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254-1260. doi:10.408/JCP.14m09168
2. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260-267. doi:10.1/j.160-047.206.0982.x PubMed
3. Sim K, Su A, Ungvari GS, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol. 2004;19(2):103-109. doi:10.102/hup.571 PubMed
4. Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health. 2008;11(1):48-56. doi:10.1/j.1524-473.207.0214.x PubMed
5. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al; CGS Study Group. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134(2-3):187-194. doi:10.1016/j.schres.201.10.02 PubMed
6. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609. doi:10.176/api.ajp.201.108124 PubMed
7. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224. doi:10.136/bmj.381.38275.2F PubMed
8. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31. PubMed
9. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Longacting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851. doi:10.1056/NEJMoa105987 PubMed
10. Buckley PF, Schooler NR, Goff DC, et al; the PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: The PROACTIVE Study. Schizophr Bull. 2014. doi:10.1093/schbul/sbu067 PubMed
11. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568-575. doi:10.408/JCP.12r08167 PubMed
12. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790-799. doi:10.408/JCP.v69n0512 PubMed
13. De la Gándara J, San Molina L, Rubio G, et al. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: The SPHERE Study. Expert Rev Neurother. 2009;9(10):1463-1474. doi:10.1586/ern.09.96 PubMed
14. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001. doi:10.1093/schbul/sbm137 PubMed
15. Hamann J, Kissling W, Heres S. Checking the plausibility of psychiatrists arguments for not prescribing depot medication. Eur Neuropsychopharmacol. 2014;24:1506-1510. doi:10.1016/j.euroneuro.2014.06.015 PubMed
16. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948-1953. doi:10.408/JCP.v67n1216 PubMed
17. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175(1-2):58-62. doi:10.1016/j.psychres.208.1.03 PubMed
18. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)6073-3 PubMed
19. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135-144. doi:10.192/bjp.bp.13.134213 PubMed
20. Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013;28(4):171-176. PubMed
21. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. doi:10.101/archpsyc.56.3.241 PubMed
22. Adler L, Tanaka Y, Williams D, et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol. 2014;34(4):461-466. doi:10.1097/JCP.0138 PubMed
23. Alphs L, Benedetti F, Fleischhacker WW, et al. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol. 2012;15(7):1003-1014. doi:10.1017/S1461457101738 PubMed
24. Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2008;34(2):275-285. doi:10.1093/schbul/sbm159 PubMed
25. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238. doi:10.1016/j.schres.205.04.08 PubMed
26. Heres S, Hamann J, Mendel R, et al. Identifying the profile of optimal candidates for antipsychotic depot therapy: A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1987-1993. doi:10.1016/j.pnpbp.208.09.025 PubMed
27. Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275-282. doi:10.1097/YIC.0b013e3280c28424 PubMed
28. Hamann J, Heres S. Adapting shared decision making for individuals with severe mental illness. Psychiatr Serv. In press.